EndoChoice receives “strong buy” rating, FDA warns against AbbVie’s Hep C drugs — 4 GI/endoscopy company key notes

Here are four recent news updates on gastroenterology and endoscopy companies.

Advertisement

Rebiotix, a Minnesota-based biotechnology company, and McMaster Children’s Hospital, based in Ontario, Canada, have started the PediFETCh clinical trial.

NDS Surgical Imaging received the 2015 Excellence in Surgical Products Award.

EndoChoice stock earned a “strong buy” rating from four analysts.

The FDA has issued a safety communication regarding Viekira Pak and Technivie, which are hepatitis C treatments manufactured by AbbVie.

More articles on GI/endoscopy:

Advertisement

Next Up in GI & Endoscopy

  • General gastroenterologists earn an average base salary of $526,273 — more than $218,000 higher than their pediatric counterparts, who report…

  • The MUSC Shawn Jenkins Children’s Hospital in Charleston, S.C., has launched the MUSC Advanced Pediatric Endoscopy Program and Pancreas Center. …

Advertisement

Comments are closed.